Lineage Cell (Israel) Performance
| LCTX Stock | ILA 211.20 209.09 9,909% |
Lineage Cell holds a performance score of 9 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of 68.53, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Lineage Cell will likely underperform. Use Lineage Cell Therape sortino ratio, maximum drawdown, and the relationship between the total risk alpha and treynor ratio , to analyze future returns on Lineage Cell Therape.
Risk-Adjusted Performance
9 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Lineage Cell Therapeutics, are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Lineage Cell sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
| Quick Ratio | 10.21 | |
| Fifty Two Week Low | 2.22 | |
| Fifty Two Week High | 820.10 |
Lineage |
Lineage Cell Relative Risk vs. Return Landscape
If you would invest 34,030 in Lineage Cell Therapeutics, on September 2, 2024 and sell it today you would lose (12,910) from holding Lineage Cell Therapeutics, or give up 37.94% of portfolio value over 90 days. Lineage Cell Therapeutics, is generating 18.4451% of daily returns and assumes 147.0805% volatility on return distribution over the 90 days horizon. Simply put, majority of traded equity instruments are less risky than Lineage on the basis of their historical return distribution, and most equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Lineage Cell Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Lineage Cell's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Lineage Cell Therapeutics,, and traders can use it to determine the average amount a Lineage Cell's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1254
| Best Portfolio | Best Equity | LCTX | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 147.08 actual daily | 96 96% of assets are less volatile |
Expected Return
| 5.01 actual daily | 96 96% of assets have lower returns |
Risk-Adjusted Return
| 0.13 actual daily | 9 91% of assets perform better |
Based on monthly moving average Lineage Cell is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Lineage Cell by adding it to a well-diversified portfolio.
Lineage Cell Fundamentals Growth
Lineage Stock prices reflect investors' perceptions of the future prospects and financial health of Lineage Cell, and Lineage Cell fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Lineage Stock performance.
| Return On Equity | -10.82 | |||
| Return On Asset | -13.19 | |||
| Current Valuation | 1.3 B | |||
| Revenue | 1.83 M | |||
| EBITDA | (24.77 M) | |||
| Cash And Equivalents | 68.75 M | |||
| Cash Per Share | 0.41 X | |||
| Total Debt | 2.9 M | |||
| Debt To Equity | 0.02 % | |||
| Book Value Per Share | 0.63 X | |||
| Cash Flow From Operations | (23.33 M) | |||
| Earnings Per Share | (0.14) X | |||
About Lineage Cell Performance
By analyzing Lineage Cell's fundamental ratios, stakeholders can gain valuable insights into Lineage Cell's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Lineage Cell has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Lineage Cell has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California. LINEAGE CELL is traded on Tel Aviv Stock Exchange in Israel.Things to note about Lineage Cell Therape performance evaluation
Checking the ongoing alerts about Lineage Cell for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Lineage Cell Therape help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Lineage Cell Therape is way too risky over 90 days horizon | |
| Lineage Cell Therape appears to be risky and price may revert if volatility continues | |
| Lineage Cell Therape has a very high chance of going through financial distress in the upcoming years | |
| The company reported the revenue of 1.83 M. Net Loss for the year was (11.93 M) with profit before overhead, payroll, taxes, and interest of 1.44 M. | |
| Lineage Cell Therapeutics, has accumulated about 68.75 M in cash with (23.33 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.41. |
- Analyzing Lineage Cell's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Lineage Cell's stock is overvalued or undervalued compared to its peers.
- Examining Lineage Cell's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Lineage Cell's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Lineage Cell's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Lineage Cell's stock. These opinions can provide insight into Lineage Cell's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Lineage Stock analysis
When running Lineage Cell's price analysis, check to measure Lineage Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lineage Cell is operating at the current time. Most of Lineage Cell's value examination focuses on studying past and present price action to predict the probability of Lineage Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lineage Cell's price. Additionally, you may evaluate how the addition of Lineage Cell to your portfolios can decrease your overall portfolio volatility.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |